|
Larotrectinib
- 英文名称：Larotrectinib
- 品牌：WYTSCI
- 产地：进口
- 型号：1MG
- 货号：WT-AY-B11430
- cas：1223403-58-4
- 价格： ￥1/mg
- 发布日期： 2025-04-10
- 更新日期： 2025-06-21
产品详请
| 产地 | 进口 |
| 品牌 | WYTSCI |
| 货号 | WT-AY-B11430 |
| 用途 | 科研检测 |
| 英文名称 | Larotrectinib |
| 包装规格 | 1MG |
| CAS编号 | 1223403-58-4 |
| 别名 | Larotrectinib |
| 纯度 | 98+% |
| 分子式 | |
| 是否进口 | 是 |
纯度:98% by HPLC;NMR (Conforms)
分子式:C21H22F2N6O2
分子量:428.44
溶剂:DMSO (5 mg/ml)
性状:Yellow solid
存储:RT
Activity (short version):panTRK inhibitor
Function / Pharmacology:Larotrectinib is a potent (IC50’s < 11 nM) inhibitor of tropomyosin receptor kinases A, B, and C (TrkA, B, and C).1 It is >100 fold selective against a panel of 229 kinases. Larotrectinib markedly attenuated bone cancer pain and significantly blocked the formation of neuroma-like structures and the sprouting of sensory nerve fibers. Larotrectinib caused substantial tumor regression in various cancers displaying TRK gene fusions.2-4 Larotrectinib is the first tissue agnostic drug approved by the FDA.
分子式:C21H22F2N6O2
分子量:428.44
溶剂:DMSO (5 mg/ml)
性状:Yellow solid
存储:RT
Activity (short version):panTRK inhibitor
Function / Pharmacology:Larotrectinib is a potent (IC50’s < 11 nM) inhibitor of tropomyosin receptor kinases A, B, and C (TrkA, B, and C).1 It is >100 fold selective against a panel of 229 kinases. Larotrectinib markedly attenuated bone cancer pain and significantly blocked the formation of neuroma-like structures and the sprouting of sensory nerve fibers. Larotrectinib caused substantial tumor regression in various cancers displaying TRK gene fusions.2-4 Larotrectinib is the first tissue agnostic drug approved by the FDA.
